オハイオにおける急性骨髄性白血病の臨床試験
オハイオ内の拠点で、急性骨髄性白血病に関する57件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
60歳以上 · 全性別 · 2026/10/02更新 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- 他44件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Gabrail Cancer Center, Canton
- Miami Valley Hospital South, Centerville
- Oncology Hematology Care, Cincinnati
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03874052A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他4件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
被験者募集中第1/2相
30 Days · 全性別 · 2026/09/16更新 · NCT04065399Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03471260Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06846606A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- The Ohio Sate University, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06969430Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT04049539Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Rainbow Babies and Childrens Hospital, Cleveland
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Cincinnati, Cincinnati
- OhioHealth Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
被験者募集中観察研究
0歳以上 · 全性別 · 2026/09/02更新 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Cincinnati OH-CINCY, Cincinnati
- US-Colombus OH-OSU, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Cincinnati OH-CINCY, Cincinnati
- US-Colombus OH-OSU, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07223814Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06930352Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/25更新 · NCT06533761A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他3件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Nationwide Children's Hospital, Columbus
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2/3相
18歳〜80歳 · 全性別 · 2026/08/05更新 · NCT06788756Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Cincinnati Medical Center (University Hospital), Cincinnati
- The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/17更新 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Childrens Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital, Cincinnati
- University Hospitals Case Medical Center, Cleveland
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05401097Ivosidenib as Post-HSCT Maintenance for AML
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/06/18更新 · NCT06707493A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Case Western Reserve University, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/12更新 · NCT05834244SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/14更新 · NCT06222580Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
- University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/27更新 · NCT06129734Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Cincinnati Children's Hospital, Cincinnati
被験者募集中第1相
21歳以下 · 全性別 · 2026/04/22更新 · NCT05101551ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。